Vascular Closure Devices Market Research Report Information By Product Type (Passive Vascular Closure Device, Active Vascular Closure Device, and External Hemostatic Device), By Access (Femoral and Radial), By Procedures (Interventional Cardiology and Interventional Radiology), By Application (Diagnostic and Therapeutic), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

Global Vascular Closure Devices Market Overview

Vascular Closure Devices Market Size was valued at USD 1.38 Billion in 2023. The Global Vascular Closure Devices industry is projected to grow from USD 1.50 Billion in 2024 to USD 2.81 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.18% during the forecast period (2024 - 2032). Vascular closure devices (VCD) are planned to achieve accelerated hemostasis during percutaneous coronary and peripheral vascular techniques. Investigations have shown that VCDs reduce time to hemostasis (TTH) and time to the movement (TTA) compared to standard manual compressions. These are the key market drivers enhancing market growth.

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Vascular surgery is one of the surgical fields where the invention of minimally invasive methods is still underway. Angiograms are one of the most frequently utilized diagnostic procedures today in several medical disciplines, such as interventional cardiology, vascular surgery, and interventional radiology. Cardiovascular disease sufferers are becoming more prevalent, which will help the industry expand. Increased vascular catheterization procedures have been made possible by the rise in cardiovascular diseases, which will ultimately generate demand for vascular closure devices. The prevalence of valvular illnesses, myocardial infarction, and congenital heart diseases is rising, and angiographic procedures are becoming more popular since they reduce bleeding and promote a speedier return to equilibrium. At the access point, manual compression is often employed for these treatments.

Various vascular closure devices were developed to help the surgeon accomplish that goal, even if manual compression remains the preferred technique. Vascular closure devices market growth is anticipated to be boosted during the forecast period by rising cardiovascular disease prevalence, rising number of heart surgeries performed globally, beneficial reimbursement policies, and increasing focus on managing patient blood loss during surgical procedures. Innovative technologies known as vascular closure devices are created to immediately seal the tiny puncture in an artery following an angiography. These tools offer a substitute for manual compression, aid in quick puncture sealing, and obviate the need for extended compression.

Due to its biodegradable material construction and progressive disintegration for natural healing, biodegradable closure devices are increasingly in demand. The market will expand due to increasing requests for topical hemostatic medications and closure devices to enhance hemostasis. The market for other indirect vascular closure devices is expected to grow due to rising personal disposable income and market participants' increased focus on large-bore vascular closure devices. Vascular closure devices will have more profitable market expansion potential due to increasing vascular closure device approvals and a growing preference for minimally invasive procedures. The increase in obese people will also help the market expand.

The year 2023 saw Cook Medical introducing its ProGlide Vascular Closure Device. It is more effective than earlier generations of ProGlide devices.

In 2022, ENDOCOR GmbH & Co. KG obtained CE Mark for the ENSURE vascular closure device, which was designed for use in the femoral artery and represents a less invasive alternative to sutures or staples.

Transluminal Technologies LLC received FDA clearance for its TRACSEAL vascular closure device in 2022 that can be used in the radial artery as an alternative to sutures or staples with minimal invasion.

FDA approved Morris Innovative Inc.’s VASCOSEAL PRO vascular closure device in 2022, which has been developed specifically for use through femoral artery and is aimed at providing minimally invasive alternatives to sutures or staples.

For example, on May 6, 2022, Teleflex Incorporated, a provider of medical technologies, gained Health Canada approval for the MANTA Vascular Closure Device; it is deemed a biomechanically-based commercial large bore femoral arterial access site (FAAS) closure system. MANTA Device is indicated for closure of femoral arterial access sites while reducing time to hemostasis following the use of 10-20F devices or sheaths (12-25F OD) in endovascular catheterization procedures.

Similarly, Haemonetics Corporation got the FDA’s approval in September 2021 regarding the VASCADE MVP Venous Vascular Closure System.

Additionally, it also obtained United States Food and Drug Administration approval for same-day discharge after atrial fibrillation ablation using itsVascade MVP venous vascular closure system. Specifically designed for cases where multiple access site venous closures are required, this system includes Vascade MVP.

In July 2021, Vivasure Medical announced the initiation of the development program of PerQseal Blue. The basic technology behind this product is PerQseal. The company’s vascular closure device is approved for use in femoral arteries in Europe.

Vascular Closure Devices Market Trends

• Increased prevalence of cardiovascular disease in the population to boost the market growth

The rising prevalence of cardiovascular diseases in the population is one of the significant factors contributing to the market growth of the vascular closure devices. The growing focus of market players on large-bore vascular closure devices and rising personal disposable income are some of the determining factors for the growth of the other indirect vascular closure devices market. Rising approvals for vascular closure devices and a rising preference for non-invasive procedures will further generate lucrative market growth opportunities for vascular closure devices. The rising obese population will also pave the way for market growth.

However, the high cost associated with vascular closure devices will act as a restraint for market growth. The rising preference for interventional procedures using radial Access will further disrupt the market growth rate. The need for highly skilled professionals and a surge in product failures and recalls will further challenge the market.

This Vascular Closure Devices Market report provides detailed information on the latest developments, trade regulations, import and export analysis, production analysis, value chain optimization, market share, the impact of domestic and local market players, analyzes emerging revenue sources, market changing aspects, Opportunities regulations, strategic market growth analysis, market size, category market growth, application areas and dominance, product approvals, product launches, geographical expansion, technological innovations in the market. Therefore, the market CAGR of Vascular Closure Devices has been increasing globally in recent years. These are essential factors driving the Vascular Closure Devices market revenue growth.

Vascular Closure Devices Market Segment Insights

Vascular Closure Devices Product Type Insights

The market segments of Vascular Closure Devices, based on Product Type, includes Passive Vascular Closure Devices, Active Vascular Closure Devices, and External Hemostatic Devices. The Passive Vascular Closure Device segment held the majority share in 2022, contributing most of the market revenue of Vascular Closure Devices market. The large share of this segment can be attributed to the increasing number of approvals for vascular closure devices and the wide-ranging advantages associated with these devices, such as ease of use and reduced complication rates for patients.

Vascular Closure Devices Access Insights

Access has bifurcated theVascular Closure Devices market data into femoral and radial. Femoral Access has a considerable share of the market. Arterial Access is associated with fewer complications as cardiologists and physicians prefer it during interventional procedures. This segment involves interventional cardiology and interventional radiology/vascular surgery markets. The interventional cardiology segment is expected to have the essential shared attributes regarding the high prevalence of cardiovascular diseases and the increase in the obese population across the globe.

Figure 1: Vascular Closure Devices Market by Access, 2022 & 2030 (USD billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Vascular Closure Devices Procedures Insights

The Vascular Closure Devices industry has been segmented based on procedures into Interventional Cardiology and Interventional Radiology. Interventional cardiology accounted for the largest market share of the vascular closure devices, the diagnosis, and treatment of many cardiovascular diseases owing to advancements in angioplasty and cardiac stenting, and the increasing prevalence of heart diseases globally.

Vascular Closure Devices Application Insights

Based on application, the Vascular Closure Devices industry has been segmented into diagnostic and therapeutic. The diagnostic segment is expected to contribute a higher share of the market. The increasing prevalence of cardiovascular diseases, expansion of diagnostic tools and services, and development of minimally invasive techniques are boosting the adoption of vascular closure devices.

News:

To improve patient outcomes, Haemonetics Corporation, a global leader in medical technology, has announced that its VASCADE MVP® Venous Vascular Closure system has successfully treated patients for the first time in Germany. This is the first time the VASCADE system portfolio, commonly utilized in American hospitals, has been employed in a European nation. The VASCADE system, typically utilized in interventional cardiology and peripheral vascular treatments, is created for "small-bore" femoral arterial and venous closure. The VASCADE MVP system is made for "mid-bore" multi-access femoral vein closure, typically done during electrophysiology treatments. The VASCADE and VASCADE MVP systems are intended to save medical personnel time while assisting patients in achieving hemostasis more quickly and generally with fewer difficulties than manual methods.

Vascular Closure Devices Regional Insights

By Region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. North America Vascular Closure Devices market, which accounted for USD 0.5 billion in 2022, is expected to exhibit a significant CAGR growth during the study period. Well-established healthcare infrastructure, rising burden of cardiovascular diseases, rise in catheter-related procedures, and increasing demand for minimally invasive solutions in the country are driving the market growth in this Region. Heart disease is the leading cause of death in the United States, according to a February 2022 update from the Centers for Disease Control and Prevention (CDC) titled "Heart Disease Facts." It also reported that about 659,000 people in the United States die from heart disease each year. Such a high disease burden creates demand for vascular closure devices and drives market growth in this Region.

 Further, the significant countries studied in the market report are The U.S., Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: VASCULAR CLOSURE DEVICES MARKET SHARE BY REGION 2022 (%)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe's Vascular Closure Devices market accounts for the second-largest market share. The presence of significant inpatients, manufacturers, and their R&D investments are the reasons behind the considerable market share. Further, the Germany market of Vascular Closure Devices held the largest market share, and the U.K. market of Vascular Closure Devices was the fastest-growing market in the European Region.

The Asia-Pacific Vascular Closure Devices Market is expected to grow at the fastest CAGR from 2022 to 2030. The Asia Pacific region will witness lucrative growth at a high CAGR. The country's rapid development of healthcare infrastructure and full automation of medical device manufacturing and production offers lucrative opportunities for market growth in this Region. Hence, it is driving the market towards growth. Moreover, the China market of Vascular Closure Devices held the largest market share, and the India market of Vascular Closure Devices was the fastest-growing market in the Asia-Pacific region.

Vascular Closure Devices Key Market Players & Competitive Insights

Major market players are spending a lot on R&D to increase their product lines, which will help the market of Vascular Closure Devices grow even more. Market participants are also taking various strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the Vascular Closure Devices industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Manufacturing locally to reduce operating costs is one of the primary business strategies manufacturers adopt in the Vascular Closure Devices industry to benefit clients and expand the market sector. The Vascular Closure Devices industry has provided medicine with some of the most significant benefits in recent years. In the market of Vascular Closure Devices, major players such as Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Cardiva Medical Inc., Morris Innovative Inc., and others are working on expanding the market demand by investing in research and development activities.

Abbott Laboratories is an American multinational medical device and healthcare company headquartered in Abbott Park, Illinois, USA. Abbott's products include Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip. In April 2020, Abbott launched its third coronavirus (COVID-19) test and shipped it to hospitals across the United States. The serological test, also known as an antibody test, could be a critical next step in the fight against the virus. Abbott's test helps spot IgG antibodies against SARS-CoV-2.

Also, Terumo Corporation was founded in 1921 as Red Line Thermometer Corporation by a group of medical scientists led by Dr. Kitasato Shibasaburo to manufacture medical thermometers in Japan. The company's first product was "Jintan Taionkei," the first commercially available Japanese-made thermometer. The company has since expanded into a medical device manufacturer producing disposable medical supplies, cardiovascular system, and diabetes care products. In July 2021, Terumo Corporation announced the launch of the Dexcom G6 continuous glucose monitoring (CGM) system in Japan. U.S.-based Dexcom, Inc. manufactures the product, and Terumo has held an exclusive distribution agreement in Japan since the partnership in 2018. A CGM system is a medical device that supports diabetes supervision.

Key Companies in the market of Vascular Closure Devices include

• 
  

  Abbott Laboratories

  
  


• 
  

  Terumo Corporation

  
  


• 
  

  Cardinal Health Inc.

  
  


• 
  

  Cardiva Medical Inc.

  
  


• 
  

  Morris Innovative Inc.

  
  


• 
  

  Medtronic plc

  
  


• 
  

  Essential Medical Inc.

  
  


• 
  

  Merit Medical Systems Inc.

  
  


• 
  

  TZ Medical Inc.

  
  


• 
  

  Vasorum Ltd., among others

  
  

Vascular Closure Devices Industry Developments

July 2021:Vivasure Medical said it would initiate a development program for PerQseal Blue. PerQseal Blue technology is based on PerQseal. The company's vessel closure device is approved for use in the femoral artery in Europe.

January 2021:Haemonetics Corporation, a medical technology company focused on providing innovative medical solutions to improve patient outcomes, entered into a definitive agreement to acquire Cardiva Medical, Inc., a privately held manufacturer of vascular closure systems.

Vascular Closure Devices Market Segmentation

Vascular Closure Devices Product Type Outlook

• 
  

  Passive Vascular Closure Device

  
  


• 
  

  Active Vascular Closure Device

  
  


• 
  

  External Hemostatic Device

  
  

Vascular Closure Devices Access Outlook

• 
  

  Femoral

  
  


• 
  

  Radial

  
  

Vascular Closure Devices Procedures Outlook

• 
  

  Interventional Cardiology

  
  


• 
  

  Interventional Radiology

  
  

Vascular Closure Devices Application Outlook

• 
  

  Diagnostic

  
  


• 
  

  Therapeutic

  
  

Vascular Closure Devices Regional Outlook

• 
  

  North America

  
  

• 
  

  US

  
  


• 
  

  Canada

  
  

• 
  

  Europe

  
  

• 
  

  Germany

  
  


• 
  

  France

  
  


• 
  

  UK

  
  


• 
  

  Italy

  
  


• 
  

  Spain

  
  


• 
  

  Rest of Europe

  
  

• 
  

  Asia-Pacific

  
  
  
  
  • 
    

    China

    
    
  
  
  • 
    

    Japan

    
    
  
  
  • 
    

    India

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    South Korea

    
    
  
  
  • 
    

    Australia

    
    
  
  
  • 
    

    Rest of Asia-Pacific

    
    
  
  
  
  


• 
  

  Rest of the World

  
  
  
  
  • 
    

    Middle East

    
    
  
  
  • 
    

    Africa

    
    
  
  
  • 
    

    Latin America